Fosun Orinove Pharmatech, Inc.
Patent Applications and Registrations
Patent applications and USPTO patent grants for Fosun Orinove Pharmatech, Inc..The latest application filed is for "ire1a inhibitor in combination with cancer therapeutic agent for cancer treatment".
- Fosun Orinove Pharmatech, Inc. - Suzhou CN
- Fosun Orinove PharmaTech, Inc. - Suzhou, Jiangsu CN
| Patent | Date |
|---|---|
| IRE-1.alpha. inhibitors Grant 11,337,956 - Zeng , et al. May 24, 2 | 2022-05-24 |
| IRE1a INHIBITOR IN COMBINATION WITH CANCER THERAPEUTIC AGENT FOR CANCER TREATMENT App 20210260069 - ZENG; Qingping ; et al. | 2021-08-26 |
| Ire-1alpha Inhibitors App 20190314330 - ZENG; Qingping ; et al. | 2019-10-17 |
| IRE-1.alpha. inhibitors Grant 10,357,475 - Zeng , et al. July 23, 2 | 2019-07-23 |
| Ire-1alpha Inhibitors App 20180228765 - Zeng; Qingping ; et al. | 2018-08-16 |
| IRE-1.alpha. inhibitors Grant 9,981,901 - Patterson , et al. May 29, 2 | 2018-05-29 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 